Neuronal Mitochondrial Dysfunction Drives Astrocytic Mitochondrial Transfer after TBI: Reveals the Therapeutic Potential of astrocytic EV-Mito

Technical Summary: Neuronal Mitochondrial Dysfunction Drives Astrocytic Mitochondrial Transfer after TBI

Problem Statement
Traumatic brain injury (TBI) is a leading cause of disability with no FDA-approved therapeutics targeting its neurobiological consequences. A hallmark of secondary injury following TBI is mitochondrial dysfunction, particularly driven by glutamate-induced excitotoxicity and subsequent calcium overload in neurons. While intercellular mitochondrial transfer (IMT) and exogenous mitochondrial transplantation (EMT) have emerged as potential mechanisms to restore bioenergetics, the in vivo relevance of cell-type-specific mitochondrial dynamics and transfer in the central nervous system (CNS) post-TBI remains incompletely understood. Specifically, it is unclear whether astrocytes donate mitochondria to neurons to rescue function after injury, how this transfer occurs, and whether the transferred mitochondria are functionally competent.

Methodology
The study employed a multi-modal approach combining in vivo mouse models, in vitro co-cultures, and single-cell transcriptomics:

• Animal Models: The researchers utilized genetically engineered mice expressing mitochondrial-targeted reporters.
  • Global/Neuronal/Astrocytic Reporters: Mice expressing mitochondrial-targeted Dendra2 (mtD2) or GFP (mtGFP) were generated using Cre-Lox systems. Specific lines included global mtD2, neuron-specific (Camk2a-Cre) mtD2/mtGFP, and astrocyte-specific (Aldh1l1-CreERT2) mtD2/mtGFP.
  • Injury Model: A Controlled Cortical Impact (CCI) model was used to induce TBI, with assessments performed 24 hours post-injury.
• Mitochondrial Isolation and Bioenergetics:
  • Fractionation: Magnetic bead-based immunoisolation (using anti-GFP antibodies) was used to separate cell-type-specific mitochondrial fractions (neuronal soma, synaptic, non-neuronal, and astrocytic) from brain tissue.
  • Seahorse XF Analysis: Oxygen Consumption Rate (OCR) was measured in isolated mitochondrial fractions to assess bioenergetic states (State III, IV, and V respiration).
  • Morphology: Confocal microscopy with 3D reconstruction (Imaris) was used to quantify mitochondrial volume, sphericity, and distribution in somatic and synaptic compartments.
• Transfer Mechanisms:
  • In Vivo: Immunofluorescence and 3D reconstruction were used to visualize and quantify astrocyte-derived mitochondria within neuronal somata and synaptosomes.
  • In Vitro: Primary cortical neurons were co-cultured with astrocytes or treated with astrocyte-conditioned media enriched for extracellular vesicles containing mitochondria (EV-mito).
  • EV-mito Enrichment: Astrocyte-conditioned media was centrifuged to isolate EV-mito, which were characterized via Western blot (CD63) and fluorescence.
• Transcriptomics: Single-cell RNA sequencing (scRNA-seq) was performed on astrocytes isolated 24 hours post-CCI to identify gene expression changes related to mitochondrial biogenesis, extracellular vesicle (EV) biogenesis, and intercellular communication.
• Functional Rescue: Primary neurons were subjected to NMDA-induced excitotoxicity and subsequently treated with isolated astrocytic EV-mito. Mitochondrial stress tests (MST) were conducted to measure the rescue of bioenergetic function.

Key Results

1. Differential Mitochondrial Dysfunction:

   • Neurons: TBI caused significant mitochondrial dysfunction in neurons, characterized by altered morphology (increased sphericity, reduced volume) and reduced bioenergetic capacity. Crucially, this dysfunction was compartment-specific: synaptic mitochondria exhibited the most severe respiratory deficits, while somatic mitochondria were less affected.
   • Astrocytes: In contrast, astrocytic mitochondria showed morphological changes (fission-like phenotype) in the cortex but preserved bioenergetic function (normal OCR) in both the cortex and hippocampus 24 hours post-injury.

2. Astrocyte-to-Neuron Mitochondrial Transfer:

   • TBI significantly increased the transfer of mitochondria from astrocytes to neuronal somata.
   • However, this transfer did not significantly increase at the synaptic level. This spatial mismatch correlates with the observed functional data: somatic bioenergetics were relatively preserved (likely due to transfer), while synaptic bioenergetics remained severely compromised due to a lack of mitochondrial support.

3. Transcriptional Reprogramming of Astrocytes:

   • scRNA-seq revealed a shift in astrocyte populations from homeostatic states to injury-associated subpopulations (As-4 to As-8).
   • Injury-associated clusters showed upregulation of genes involved in extracellular vesicle (EV) biogenesis (e.g., Sdc4, Cd9, Cd63), mitochondrial translation (Mrps6, Mrpl33), and cytoskeletal remodeling (TNT formation). This suggests an active, adaptive response to facilitate mitochondrial trafficking.

4. Therapeutic Potential of EV-mito:

   • In vitro experiments confirmed that astrocytes transfer mitochondria to neurons via EVs (and tunneling nanotubes).
   • Treatment of NMDA-injured neurons with isolated astrocytic EV-mito significantly restored basal respiration and ATP production. This rescue effect was specific to the injured (dysfunctional) neurons, indicating that exogenous EV-mito can integrate and functionally compensate for endogenous deficits.

Significance and Claims
The authors claim that this study identifies astrocytic mitochondrial transfer as an endogenous neuroprotective response to TBI. The central finding is that neuronal mitochondrial dysfunction drives astrocytes to adopt a supportive phenotype, releasing functional mitochondria via EVs to rescue somatic bioenergetics.

The paper highlights a critical spatial limitation in this natural repair mechanism: while astrocytes successfully deliver mitochondria to neuronal somata, they fail to adequately supply synaptic compartments, leaving synapses vulnerable to excitotoxicity.

The study positions astrocyte-derived EV-mito as a promising therapeutic strategy. By demonstrating that exogenous EV-mito can rescue mitochondrial function in excitotoxic conditions, the authors suggest that harnessing this mechanism could address the specific bioenergetic deficits associated with TBI and other neurodegenerative disorders characterized by mitochondrial dysfunction. The work bridges the gap between understanding endogenous repair mechanisms and developing exogenous mitochondrial transplantation therapies.